{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:35:34Z","timestamp":1791974134855,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Junge Akademie, Hannover Medical School"},{"name":"CIBERES","award":["CB07\/06\/2008"],"award-info":[{"award-number":["CB07\/06\/2008"]}]},{"name":"ERC grant longheart"},{"name":"DFG TRR_267","award":["TRR_267"],"award-info":[{"award-number":["TRR_267"]}]},{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hypertrophic cardiomyopathy (HCM) is one of the most common hereditary heart diseases and can be classified into an obstructive (HOCM) and non-obstructive\u00a0(HNCM) form. Major characteristics for HCM are the hypertrophy of cardiomyocytes and development of cardiac fibrosis. Patients with HCM have a higher risk for sudden cardiac death compared to a healthy population. In the present study, we investigated the abundancy of selected proteins as potential biomarkers in patients with HCM. We included 60 patients with HCM and 28 healthy controls and quantitatively measured the rate of a set of 92 proteins already known to be associated with cardiometabolic processes via protein screening using the proximity extension assay technology in a subgroup of these patients (20 HCM and 10 healthy controls). After validation of four hits in the whole cohort of patients consisting of 88 individuals (60 HCM patients, 28 healthy controls) we found only one candidate, c-KIT, which was regulated significantly different between HCM patients and healthy controls and thus was chosen for further analyses. c-KIT is a tyrosine-protein kinase acting as receptor for the stem cell factor and activating several pathways essential for cell proliferation and survival, hematopoiesis, gametogenesis and melanogenesis. Serum protein levels of c-KIT were significantly lower in patients with HCM than in healthy controls, even after adjusting for confounding factors age and sex. In addition, c-KIT levels in human cardiac tissue of patients with HOCM were significant higher compared to controls indicating high levels of c-KIT in fibrotic myocardium. Furthermore, c-KIT concentration in serum significantly correlated with left ventricular end-diastolic diameter in HOCM, but not HCM patients. The present data suggest c-KIT as a novel biomarker differentiating between patients with HCM and healthy population and might provide further functional insights into fibrosis-related processes of HOCM.<\/jats:p>","DOI":"10.1038\/s41598-020-80868-z","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T11:09:05Z","timestamp":1611054545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Blood-based protein profiling identifies serum protein c-KIT as a novel biomarker for hypertrophic cardiomyopathy"],"prefix":"10.1038","volume":"11","author":[{"given":"Kristina","family":"Sonnenschein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"de Gonzalo-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Pfanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Just","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Zwadlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Bavendiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresia","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristobal","family":"Dos Remedios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serghei","family":"Cebotari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Thum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"key":"80868_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron, B. J. Clinical course and management of hypertrophic cardiomyopathy. N. Engl. J. Med. 379, 655\u2013668 (2018).","journal-title":"N. Engl. J. Med."},{"key":"80868_CR2","doi-asserted-by":"crossref","unstructured":"Authors\/Task Force membersmembers, A. F. et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 35, 2733\u20132779 (2014).","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"80868_CR3","doi-asserted-by":"publisher","first-page":"20350","DOI":"10.1038\/s41598-019-56617-2","volume":"9","author":"K Sonnenschein","year":"2019","unstructured":"Sonnenschein, K. et al. Serum circular RNAs act as blood-based biomarkers for hypertrophic obstructive cardiomyopathy. Sci. Rep. 9, 20350\u201320352 (2019).","journal-title":"Sci. Rep."},{"key":"80868_CR4","doi-asserted-by":"publisher","first-page":"H707","DOI":"10.1152\/ajpheart.00194.2016","volume":"311","author":"J Kitow","year":"2016","unstructured":"Kitow, J. et al. (2016) Mitochondrial long noncoding RNAs as blood based biomarkers for cardiac remodeling in patients with hypertrophic cardiomyopathy. Am. J. Physiol. Hear. Circ. Physiol. 311, H707\u2013H712 (2016).","journal-title":"Am. J. Physiol. Hear. Circ. Physiol."},{"key":"80868_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijcard.2015.05.185","volume":"196","author":"AA Derda","year":"2015","unstructured":"Derda, A. A. et al. Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy. Int. J. Cardiol. 196, 115\u2013122 (2015).","journal-title":"Int. J. Cardiol."},{"key":"80868_CR6","doi-asserted-by":"crossref","unstructured":"Huang, D. et al. MicroRNA-221 is a potential biomarker of myocardial hypertrophy and fibrosis in hypertrophic obstructive cardiomyopathy. Biosci. Rep. 40(1), BSR20191234  (2020).","DOI":"10.1042\/BSR20191234"},{"key":"80868_CR7","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jacc.2013.09.041","volume":"63","author":"R Roncarati","year":"2014","unstructured":"Roncarati, R. et al. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 63, 920\u2013927 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"80868_CR8","first-page":"100452","volume":"26","author":"P Magnusson","year":"2020","unstructured":"Magnusson, P. et al. Positron emission tomography ((15)O-water, (11)C-acetate, (11)C-HED) risk markers and nonsustained ventricular tachycardia in hypertrophic cardiomyopathy. Int. J. Cardiol. Hear. Vasc. 26, 100452 (2020).","journal-title":"Int. J. Cardiol. Hear. Vasc."},{"key":"80868_CR9","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/ehjci\/jez213","volume":"20","author":"F Ricci","year":"2019","unstructured":"Ricci, F. et al. Pulmonary blood volume index as a quantitative biomarker of haemodynamic congestion in hypertrophic cardiomyopathy. Eur. Heart J. Cardiovasc. Imaging 20, 1368\u20131376 (2019).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"80868_CR10","first-page":"196","volume":"106","author":"C B\u00e9gu\u00e9","year":"2020","unstructured":"B\u00e9gu\u00e9, C. et al. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy. Heart 106, 196\u2013202 (2020).","journal-title":"Heart"},{"key":"80868_CR11","doi-asserted-by":"publisher","first-page":"e001974","DOI":"10.1161\/CIRCGENETICS.117.001974","volume":"11","author":"CJ Coats","year":"2018","unstructured":"Coats, C. J. et al. Proteomic analysis of the myocardium in hypertrophic obstructive cardiomyopathy. Circ. Genomic Precis. Med. 11, e001974 (2018).","journal-title":"Circ. Genomic Precis. Med."},{"key":"80868_CR12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/cvr\/cvy147","volume":"114","author":"J van der Velden","year":"2018","unstructured":"van der Velden, J. et al. Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of myocardial function of the European Society of Cardiology. Cardiovasc. Res. 114, 1273\u20131280 (2018).","journal-title":"Cardiovasc. Res."},{"key":"80868_CR13","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","volume":"141","author":"CN Toepfer","year":"2020","unstructured":"Toepfer, C. N. et al. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation 141, 828\u2013842 (2020).","journal-title":"Circulation"},{"key":"80868_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0168-9525(03)00081-7","volume":"19","author":"H Ashrafian","year":"2003","unstructured":"Ashrafian, H., Redwood, C., Blair, E. & Watkins, H. Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion. Trends Genet. 19, 263\u2013268 (2003).","journal-title":"Trends Genet."},{"key":"80868_CR15","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1074\/jbc.M312323200","volume":"279","author":"AC Cruz","year":"2004","unstructured":"Cruz, A. C. et al. Tumor necrosis factor-alpha-converting enzyme controls surface expression of c-Kit and survival of embryonic stem cell-derived mast cells. J. Biol. Chem. 279, 5612\u20135620 (2004).","journal-title":"J. Biol. Chem."},{"key":"80868_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s12079-017-0399-1","volume":"11","author":"HJ Cardoso","year":"2017","unstructured":"Cardoso, H. J., Figueira, M. I. & Socorro, S. The stem cell factor (SCF)\/c-KIT signalling in testis and prostate cancer. J. Cell Commun. Signal. 11, 297\u2013307 (2017).","journal-title":"J. Cell Commun. Signal."},{"key":"80868_CR17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.V90.4.1345","volume":"90","author":"VC Broudy","year":"1997","unstructured":"Broudy, V. C. Stem cell factor and hematopoiesis. Blood 90, 1345\u20131364 (1997).","journal-title":"Blood"},{"key":"80868_CR18","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.7150\/thno.41616","volume":"10","author":"J Tang","year":"2020","unstructured":"Tang, J. et al. Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma. Theranostics 10, 5384\u20135397 (2020).","journal-title":"Theranostics"},{"key":"80868_CR19","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.7150\/thno.22027","volume":"8","author":"S Fujimoto","year":"2018","unstructured":"Fujimoto, S. et al. A novel theranostic combination of near-infrared fluorescence imaging and laser irradiation targeting c-KIT for gastrointestinal stromal tumors. Theranostics 8, 2313\u20132328 (2018).","journal-title":"Theranostics"},{"key":"80868_CR20","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","volume":"29","author":"J Guo","year":"2011","unstructured":"Guo, J. et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29, 2904\u20132909 (2011).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"80868_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2020.05.045","author":"J-O Kim","year":"2020","unstructured":"Kim, J.-O. et al. Development and characterization of a fully human antibody targeting SCF\/c-kit signaling. Int. J. Biol. Macromol. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.05.045 (2020).","journal-title":"Int. J. Biol. Macromol."},{"key":"80868_CR22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000376573","volume":"91","author":"C Koch","year":"2015","unstructured":"Koch, C. & Trojan, J. Established and potential predictive biomarkers in gastrointestinal cancer\u2013c-Kit, Her2, ras and beyond.  Digestion 91, 294\u2013302 (2015).","journal-title":"Digestion"},{"key":"80868_CR23","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-08-2480","volume":"15","author":"SE Deprimo","year":"2009","unstructured":"Deprimo, S. E. et al. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure . Clin. cancer Res. Off J. Am. Assoc. Cancer Res. 15, 5869\u20135877 (2009).","journal-title":"Clin. cancer Res. Off J. Am. Assoc. Cancer Res."},{"key":"80868_CR24","doi-asserted-by":"publisher","first-page":"1824863","DOI":"10.1080\/2162402X.2020.1824863","volume":"9","author":"SG Kalathil","year":"2020","unstructured":"Kalathil, S. G., Wang, K., Hutson, A., Iyer, R. & Thanavala, Y. Tivozanib mediated inhibition of c-Kit\/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients. Oncoimmunology 9, 1824863 (2020).","journal-title":"Oncoimmunology"},{"key":"80868_CR25","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1158\/1078-0432.CCR-18-1897","volume":"25","author":"K Tarlock","year":"2019","unstructured":"Tarlock, K. et al. Functional Properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia . Clin. Cancer Res. Off J. Am. Assoc. Cancer Res. 25, 5038\u20135048 (2019).","journal-title":"Clin. Cancer Res. Off J. Am. Assoc. Cancer Res."},{"key":"80868_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/path.4177","volume":"230","author":"L Ding","year":"2013","unstructured":"Ding, L. et al. Essential role of stem cell factor-c-Kit signalling pathway in bleomycin-induced pulmonary fibrosis. J. Pathol. 230, 205\u2013214 (2013).","journal-title":"J. Pathol."},{"key":"80868_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44\u201357 (2009).","journal-title":"Nat. Protoc."},{"key":"80868_CR28","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","volume":"79","author":"Y Lamb","year":"2019","unstructured":"Lamb, Y. N. pexidartinib: first approval. Drugs 79, 1805\u20131812 (2019).","journal-title":"Drugs"},{"key":"80868_CR29","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1161\/CIRCRESAHA.109.210088","volume":"106","author":"M Meloni","year":"2010","unstructured":"Meloni, M. et al. Nerve growth factor promotes cardiac repair following myocardial infarction. Circ. Res. 106, 1275\u20131284 (2010).","journal-title":"Circ. Res."},{"key":"80868_CR30","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1161\/01.RES.0000243210.79654.fd","volume":"99","author":"C-H Wang","year":"2006","unstructured":"Wang, C.-H. et al. Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate. Circ. Res. 99, 617\u2013625 (2006).","journal-title":"Circ. Res."},{"key":"80868_CR31","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1182\/blood.V83.8.2145.2145","volume":"83","author":"VC Broudy","year":"1994","unstructured":"Broudy, V. C. et al. Human umbilical vein endothelial cells display high-affinity c-kit receptors and produce a soluble form of the c-kit receptor. Blood 83, 2145\u20132152 (1994).","journal-title":"Blood"},{"key":"80868_CR32","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1182\/blood.V85.8.2052.bloodjournal8582052","volume":"85","author":"AM Turner","year":"1995","unstructured":"Turner, A. M. et al. Identification and characterization of a soluble c-kit receptor produced by human hematopoietic cell lines. Blood 85, 2052\u20132058 (1995).","journal-title":"Blood"},{"key":"80868_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1182\/blood.V85.1.66.bloodjournal85166","volume":"85","author":"J Wypych","year":"1995","unstructured":"Wypych, J. et al. Soluble kit receptor in human serum. Blood 85, 66\u201373 (1995).","journal-title":"Blood"},{"key":"80868_CR34","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10517-012-1761-1","volume":"153","author":"TV Sukhacheva","year":"2012","unstructured":"Sukhacheva, T. V. et al. Resident stem cells in the myocardium of patients with obstructive hypertrophic cardiomyopathy. Bull. Exp. Biol. Med. 153, 535\u2013539 (2012).","journal-title":"Bull. Exp. Biol. Med."},{"key":"80868_CR35","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9, e95192 (2014).","journal-title":"PLoS ONE"},{"key":"80868_CR36","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/pmic.201300334","volume":"14","author":"C Solier","year":"2014","unstructured":"Solier, C. & Langen, H. Antibody-based proteomics and biomarker research\u2014current status and limitations. Proteomics 14, 774\u2013783 (2014).","journal-title":"Proteomics"},{"key":"80868_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/jcm9010195","volume":"9","author":"E Bouwens","year":"2020","unstructured":"Bouwens, E. et al. Circulating biomarkers of cell adhesion predict clinical outcome in patients with chronic heart failure. J. Clin. Med. 9, 195 (2020).","journal-title":"J. Clin. Med."},{"key":"80868_CR38","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/cvr\/cvz063","volume":"115","author":"K Sonnenschein","year":"2019","unstructured":"Sonnenschein, K. et al. Therapeutic modulation of RNA-binding protein Rbm38 facilitates re-endothelialization after arterial injury. Cardiovasc. Res. 115, 1804\u20131810 (2019).","journal-title":"Cardiovasc. Res."},{"key":"80868_CR39","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.omtn.2019.09.003","volume":"18","author":"F Kenneweg","year":"2019","unstructured":"Kenneweg, F. et al. Long noncoding RNA-enriched vesicles secreted by hypoxic cardiomyocytes drive cardiac fibrosis. Mol. Ther. Nucleic Acids 18, 363\u2013374 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"80868_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"80868_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa970","author":"M Kanehisa","year":"2020","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Ishiguro-Watanabe, M. & Tanabe, M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkaa970 (2020).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80868-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80868-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80868-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:12:28Z","timestamp":1670033548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80868-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["80868"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-80868-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"2 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.T. has filed patents in the field of non-coding RNAs and is founder and holds shares of Cardior Pharmaceuticals GmbH. Other authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1755"}}